Cholangiocarcinoma
Conditions
Interventions
Control group 1:Tumor Dual Immunotherapy Regimen (Tirilizumab Injection + Thymofaxine Injection). Tirilizumab Injection is administered by intravenous infusion at a recommended dose of 200 mg by intra
Control group 2:Only the tumor immunosuppressant (Tirilizumab injection) was administered. Tirilizumab Injection is administered by intravenous infusion at a recommended dose of 200 mg by intravenous
Observer group:Xihuang Pills combined with tumor double immunization ( Tirelizumab Injection + Thymalfasin Injection )
Xihuang Pills (Tongrentang Pharmaceuticals, Lot No. 20130619), 3g /times, 2 times/d, the course of treatment is 2 months. Xihuang Pills Usage and Dosage: Oral. 3g once, twice a day. Tirilizumab Inject
Sponsors
Affiliated Hospital of Jiangnan University
Eligibility
Sex/Gender
All
Age
35 Years to 80 Years
Inclusion criteria
Inclusion criteria: ( 1 ) TNM stage IV ; ( 2 ) TCM syndrome differentiation is damp heat poly poison syndrome ; ( 3 ) The estimated survival time = 6 months ; ( 4 ) Meet the treatment indications, Karnofsky score = 60 points ; ( 5 ) The ethics committee passed, and the patients and their families signed the informed consent.
Exclusion criteria
Exclusion criteria: ( 1 ) Patients with severe heart, lung, liver, kidney and other organ diseases ; ( 2 ) Combined with other malignant tumors ; ( 3 ) Age 100µmol / L.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Coagulation function;Immune function;Tumor marker; | — |
Countries
China
Contacts
Public ContactPeng Wang
Affiliated Hospital of Jiangnan University
Outcome results
None listed